David Greenwald

David Greenwald is a partner in Cravath, Swaine & Moore LLP’s litigation department. He practises general commercial litigation, with a focus on patent litigation (particularly concerning chemical, pharmaceutical and biotechnological patents) and white collar criminal defence. Mr Greenwald is a patent attorney registered with the USPTO.

Mr Greenwald’s representative patent matters have included:

• representation in patent litigation under the Biologics Price Competition and Innovation Act of the first biological drug company to obtain approval to market a biosimilar of Humira, the world’s largest selling drug;
• representation at trial of a major pharmaceutical company in Hatch-Waxman Act actions to enjoin approval of generic versions of Posaconazole, a drug indicated for prevention of life-threatening fungal infections;
• representation of a biopharmaceutical company in a patent licensing dispute with a medical research centre, involving rights to CAR-T cancer therapy technology;
• representation of a biological drug company in a patent infringement action involving patents covering PCSK9 inhibitors, biologic drugs indicated for the reduction of low-density lipoprotein cholesterol;
• representation at trial of a pharmaceutical company in a Hatch-Waxman action to enforce patents covering formulations of Formoterol, a drug indicated for the treatment of chronic obstructive pulmonary disease;
• representation at trial of a pharmaceutical company in a federal action to enforce a patent covering the most widely prescribed prescription anti-coagulant drug;
• representation of a pharmaceutical company in an appeal from an adverse judgment enjoining generic entry of a drug indicated for the treatment of AIDS;
• representation before federal district courts of various other pharmaceutical companies in actions to enjoin approval and marketing of generic versions of patented drugs; and
• representation of a major biotechnology company in an action asserting infringement of a patent claiming improved methods for expressing proteins in mammalian cells.

Mr Greenwald received a BA, summa cum laude, in biochemical sciences from Harvard College in 1990 and a JD with high honours from the University of Chicago in 1993.